AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
DBV Technologies (NASDAQ:DBVT)
16.75 USD
-1.370 7.561%Sponsored Reports
Loading...
| Previous Close (in USD) | 18.12 |
|---|---|
| Change | -1.370 7.561% |
| 52 W H/L (in USD) | 26.185/7.526 |
| EBITDA (in USD) | -143.862M |
| PE Ratio | -- |
| Volume | 160831 |
| Diluted Eps TTM | -5.25 |
| Total Assets (in USD) | 233.718M |
|---|---|
| Total Liabilities (in USD) | 64.948M |
| Revenue TTM (in USD) | 5.636M |
| Cash (in USD) | 194.167M |
| Market Cap (in USD) | 1,181.882 M |
| Revenue Per Share TTM | 0.200 |
| Gross Profit TTM (in USD) | 5.636M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Employees: 117
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Daniel Tassé | CEO & Director | 1960 |
| 2. | Mr. Sébastien Robitaille | Chief Financial Officer | 1970 |
| 3. | Dr. Pharis Mohideen | Chief Medical Officer | 1965 |
| 4. | Mr. Pascal Wotling | Chief Technical Operations Officer & Chief Quality Officer | NA |
| 5. | Anne Pollak | Head of Investor Relations | NA |
| 6. | Ms. Michele F. Robertson | Chief Legal Officer | NA |
| 7. | Joseph Becker | VP of Global Corp. Communications | NA |
| 8. | Ms. Caroline Daniere | Chief HR Officer & Chief of Staff | 1975 |
| 9. | Dr. Wence Agbotounou | Chief Clinical Trial Officer & Sr. VP | NA |
| 10. | Ms. Lucie Mondoulet | Sr. VP & Deputy CSO | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.370 0.842% | 44.03 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.001 0.003% | 44.4 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+2.710 0.602% | 452.82 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.250 0.041% | 615.18 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -152.563M | -117.801M | -72.719M | -96.2M | -98.19M |
| Minority Interest | - | - | - | - | - |
| Net Income | -147.402M | -113.717M | -72.726M | -96.3M | -97.809M |
| Selling General Administrative | 15.984M | 28.739M | 29.5M | 24.3M | 30.52M |
| Gross Profit | -17.675M | -6.814M | 15.728M | 4.8M | 5.708M |
| Reconciled Depreciation | 3.194M | -0.925M | 8.95M | 13.162M | 8.376M |
| Ebit | -153.164M | -117.801M | -76.433M | -96.631M | -98.614M |
| Ebitda | -135.49M | -110.987M | -63.271M | -96.6M | -100.455M |
| Depreciation And Amortization | 17.675M | 6.814M | 13.162M | 0.031M | -1.841M |
| Operating Income | -153.164M | -120.527M | -76.432M | -96.631M | -98.614M |
| Other Operating Expenses | 153.164M | 120.527M | 92.16M | 101.4M | 105.243M |
| Interest Expense | - | 0.74M | - | 0.427M | 10.641M |
| Tax Provision | 0.491M | 0.055M | -0.004M | 0.07M | -0.381M |
| Interest Income | - | - | - | - | - |
| Net Interest Income | 0.601M | 2.726M | 1.743M | 0.427M | 0.425M |
| Income Tax Expense | -5.161M | -4.084M | 0.007M | 0.1M | -0.381M |
| Total Revenue | 0M | 2.568M | 15.728M | 4.8M | 5.708M |
| Total Operating Expenses | 40.021M | 113.713M | 92.16M | 101.4M | 105.243M |
| Cost Of Revenue | 17.675M | 6.814M | -4.497M | - | - |
| Total Other Income Expense Net | 0.602M | 2.726M | 3.713M | 0.431M | 0.424M |
| Net Income From Continuing Ops | -146.947M | -113.918M | -100.781M | -96.274M | -97.809M |
| Net Income Applicable To Common Shares | - | - | - | -96.274M | -97.809M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 233.718M | 65.658M | 182.986M | 246.5M | 146.723M |
| Intangible Assets | 0.022M | 0.04M | 0.058M | 0.01M | 0.022M |
| Other Current Assets | 2.628M | 1.541M | 2.103M | 0.001M | 0.001M |
| Total Liab | 64.948M | 38.271M | 42.8M | 52M | 47.449M |
| Total Stockholder Equity | 168.77M | 27.388M | 140.186M | 194.5M | 99.274M |
| Other Current Liab | 0.809M | 7.416M | 3.959M | 4.014M | 4.276M |
| Common Stock | 26.078M | 11.651M | 10.972M | 10.72M | 6.538M |
| Capital Stock | 26.912M | 11.651M | 10.972M | 10.72M | 6.538M |
| Retained Earnings | -393.129M | -286.375M | -238.862M | -259.578M | -258.528M |
| Good Will | - | - | - | - | - |
| Other Assets | - | -0.001M | 0M | 4.052M | 4.168M |
| Cash | 194.167M | 32.456M | 141.367M | 209.2M | 77.301M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 58.025M | 31.136M | 37.339M | 29.521M | 31.397M |
| Current Deferred Revenue | - | - | 0.223M | 2.137M | 4.146M |
| Net Debt | -172.483M | -24.659M | -126.986M | -199.176M | -58.608M |
| Short Term Debt | 16.275M | 1.5M | 9.855M | 8.897M | 11.546M |
| Short Long Term Debt | 1.468M | 0.846M | 0.883M | 7.003M | 8.543M |
| Short Long Term Debt Total | 21.684M | 7.797M | 14.381M | 10.024M | 18.693M |
| Other Stockholder Equity | 541.251M | 314.304M | 376.205M | 457.158M | 356.882M |
| Property Plant Equipment | - | - | - | 17.609M | 25.482M |
| Total Current Assets | 212.943M | 44.388M | 158.915M | 209.2M | 77.301M |
| Long Term Investments | 5.189M | 4.312M | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 16.148M | 10.391M | 15.445M | 11.199M | 32.935M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | -11.2M | -32.936M |
| Accounts Payable | 40.941M | 22.032M | 23.302M | 14.473M | 11.429M |
| Accumulated Other Comprehensive Income | -5.43M | -12.192M | -8.129M | -13.8M | -5.618M |
| Non Currrent Assets Other | 5.188M | 0.111M | 2.073M | 19.681M | 43.918M |
| Non Current Assets Total | 20.775M | 21.271M | 24.071M | 37.3M | 69.422M |
| Capital Lease Obligations | 6.526M | 6.951M | 5.67M | 3.021M | 10.15M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | - | -0.757M | -0.655M | -0.1M | -0.119M |
| Total Cashflows From Investing Activities | -1.369M | -0.757M | -0.808M | -0.1M | -0.433M |
| Total Cash From Financing Activities | 276.182M | 0.587M | 6.767M | 194.1M | 0.274M |
| Net Income | -146.947M | -113.918M | -72.726M | -96.274M | -97.809M |
| Change In Cash | 161.711M | -108.911M | -67.827M | 131.9M | -119.051M |
| Begin Period Cash Flow | 32.456M | 141.367M | 209.194M | 77.3M | 196.352M |
| End Period Cash Flow | 194.167M | 32.456M | 141.367M | 209.2M | 77.301M |
| Total Cash From Operating Activities | -121.181M | -104.474M | -79.653M | -55.7M | -108.242M |
| Depreciation | 3.194M | -0.925M | -13.998M | 13.162M | 8.376M |
| Other Cashflows From Investing Activities | -1.369M | 1.581M | -0.141M | -0.001M | -0.433M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -16.112M | -1.388M | 0M | 0M | -16.177M |
| Sale Purchase Of Stock | - | -0.047M | -0.154M | - | - |
| Other Cashflows From Financing Activities | -0.855M | - | -0.808M | -0.494M | -0.704M |
| Capital Expenditures | 0.534M | 2.341M | 0.677M | 0.754M | 0.918M |
| Change In Working Capital | 1.344M | 5.752M | 0.953M | 22.32M | -22.771M |
| Other Non Cash Items | 15.841M | -0.003M | 0.099M | 0.066M | 0.656M |
| Free Cash Flow | -121.181M | -106.815M | -80.33M | -56.454M | -109.16M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Artisan Non-U.S. Small-Mid Growth Comp | 2 months ago | 1363189 |
| 2. | Artisan International Small-Mid Investor | 2 months ago | 1363189 |
| 3. | AdvisorShares Dorsey Wright ADR ETF | 2 months ago | 50340 |
| 4. | Russell Inv Tax-Managed US Mid&Sm Cap S | 2 months ago | 45089 |
| 5. | Russell Inv US Small Cap Equity Y | 2 months ago | 22707 |
| 6. | Dorsey Wright Sys Reltv Strength Intl | 3 months ago | 18173 |
| 7. | Artisan International Small-Mid Tr Fdrs | 2 months ago | 16764 |
| 8. | Russell Inv Small Cap Fund F | 2 months ago | 15696 |
| 9. | Russell Inv Equity II | 2 months ago | 6678 |
| 10. | Russell Inv US Small Cap Equity | 2 months ago | 5834 |
| 11. | Steward Values Enhanced International I | 2 months ago | 4051 |
| 12. | Fidelity Nasdaq Composite Index | 3 months ago | 3877 |
| 13. | ST Dorsey Wright® Intl Momntm Tr 39 CA | 2 months ago | 100 |
| 14. | ST Dorsey Wright® Intl Momntm Tr 42 CA | 2 months ago | 100 |
| 15. | HJIM International Select Small Cap | 5 months ago | 40 |
| 16. | Lord Abbett Health Care R6 | 3 months ago | 2973 |
| 17. | Gabelli Health & Wellness | 5 months ago | 500 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Patient Square Capital LP | 5 months ago | 359050 |
| 2. | Vestal Point Capital LP | 5 months ago | 300000 |
| 3. | Squadron Capital Management LLC | 5 months ago | 240000 |
| 4. | Balyasny Asset Management LLC | 5 months ago | 235023 |
| 5. | New York State Common Retirement Fund | 5 months ago | 223186 |
| 6. | Atika Capital Management LLC | 5 months ago | 206881 |
| 7. | BOOTHBAY FUND MANAGEMENT, LLC | 5 months ago | 163401 |
| 8. | Citadel Advisors Llc | 5 months ago | 145129 |
| 9. | Polymer Capital Management (Hk) Ltd | 5 months ago | 64500 |
| 10. | Artisan Partners Limited Partnership | 5 months ago | 3309055 |
| 11. | Vivo Capital, LLC | 5 months ago | 2461626 |
| 12. | Siren, L.L.C. | 5 months ago | 1857362 |
| 13. | Baker Bros Advisors LP | 5 months ago | 1461425 |
| 14. | MPM Oncology Impact Management LP | 5 months ago | 996825 |
| 15. | Millennium Management LLC | 5 months ago | 640885 |
| 16. | Yiheng Capital LLC | 5 months ago | 639769 |
| 17. | Octagon Capital Advisors LP | 5 months ago | 574200 |
| 18. | Redmile Group, LLC | 5 months ago | 549840 |
| 19. | Ikarian Capital, LLC | 5 months ago | 525000 |
| 20. | Schonfeld Strategic Advisors LLC | 5 months ago | 454343 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...